RituxiRel (Rituximab) is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. At present, Rituximab is the most important mAb of clinical value in patients with B-cell lymphoid malignancies.

Rituximab has an approximate molecular weight of 145 kDa. Rituximab has a binding affinity for the CD20 antigen of approximately 8.0 nM. CD20 is expressed relatively on selected B cells from the pre-B-cell stage until post germinal cells differentiate to become plasma cells.

RituxiRel is approved for Non-Hodgkin's Lymphoma (NHL), Rheumatoid Arthritis (RA), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) and Pemphigus Vulgaris (PV).

RituxiRel comes in 100 mg/10 mL in single-use vial and 500 mg/50 mL in single use vial.